Repare Therapeutics Inc.

Repare Therapeutics Inc. (RPTX) priced its initial public offering on Jun 19, 2020 at $20.00 per share, within its $18.00–$20.00 range, raising $220M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $700.4M. Morgan Stanley was lead-left underwriter, joined by Goldman Sachs, TD Cowen and Piper Sandler. Cooley and Stikeman Elliott advised the company and Goodwin Procter advised the underwriters.

Repare Therapeutics Inc. is a precision oncology company using synthetic lethality to discover and develop cancer therapies. Its CRISPR-enabled SNIPRx platform targets genomic instability, including DNA damage repair, and its lead candidate, RP-3500, is an oral small molecule inhibitor for solid tumors.

Status

IPO

Ticker

RPTX

Exchange

Nasdaq Global Select

Priced

Jun 19, 2020

IPO price

$20.00

Price range

$18.00–$20.00

Raised

$220M

Market cap at IPO price

$700.4M

First filed

May 29, 2020

Underwriters

Morgan Stanley, Goldman Sachs, TD Cowen and Piper Sandler

Company counsel

Cooley and Stikeman Elliott

Underwriters' counsel

Goodwin Procter

Sector

Biotech & pharma

Country / state

Quebec, Canada

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.